Over the last decade, increasing evidence highlights the role of the host immune system in the control of tumor growth and the prognostic implications of tumor infiltrating lymphocytes (TILs) in ovarian cancer. Most data support a better prognosis with accumulation of CD31 and CD8 1 TILs and a poor outcome associated with increased regulatory T cells. However, only a small number of studies have focused on the effect of neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment. This review will provide an update on the prognostic value of TIL subpopulations at diagnosis and a comprehensive overview of the recent studies evaluating the impact of neoadjuvant chemotherapy on TILs and their relationship to clinical outcome in advanced ovarian cancer. This information could help in future investigations of immunotherapy as maintenance following primary treatment.
Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, affecting approximately 1 in 70 women with only 45% surviving 5 years after diagnosis. 1 Its bleak outcome is explained by the fact that >75% of patients present with advanced tumor stage (FIGOIII/IV) where the cornerstone of management rests on complete resection of all macroscopic disease and platinum-based chemotherapy. 2, 3 In patients with stage IIIC or IV disease where complete resection cannot be achieved, neoadjuvant chemotherapy followed by interval debulking surgery and adjuvant chemotherapy is a suitable alternative associated with lower morbidity. 4, 5 Although most ovarian cancer patients will respond effectively to current management (taxane/platinum-based chemotherapies and cytoreduction), 70% of them will eventually develop recurrence and chemoresistance. 6 The extent of postoperative residual tumor has been shown to have a significant prognostic impact on survival. 7 In addition, there is increasing evidence that the host immune system has a role in the control of cancer growth, and tumor infiltrating lymphocytes (TILs) have been repeatedly associated with improved survival in EOC. [8] [9] [10] [11] [12] As such, the development of approaches that mobilize tumor-reactive TILs is emerging as an attractive therapeutic strategy. Classical cytotoxic drugs have been shown to alter the local immune state which could modulate treatment efficacy by stimulating or inhibiting the host's antitumor immune response. [13] [14] [15] The neoadjuvant setting where paired ovarian tumor samples are obtained at diagnosis and at interval debulking after platinum-based chemotherapy offers a useful model to study the impact of cytotoxic treatment on the immune tumor microenvironment. This review will provide an update on the prognostic value of TIL subpopulations at diagnosis and review the recent studies evaluating the evolution of the immune infiltrate with neoadjuvant chemotherapy which could inform future investigations of immunotherapy as maintenance following primary treatment
Prognostic Impact of TILs in Treatment Naive Ovarian Cancer
Tumor infiltrating lymphocytes (TILs) have been demonstrated in ovarian tumors, suggesting an interaction between the host's immune system and the tumor. 16 TILs encompass T-cells, B-cells or natural killer (NK) cells which have traversed the vasculature localizing into tumor tissue or surrounding stroma 17 and have been implicated in the control of tumor growth. 18 Studies conducted at diagnosis on untreated tumors have confirmed the important prognostic value of TILs in several neoplasms including ovarian cancer.
In the most recent meta-analysis including 21 different studies and almost 3,000 patients, Li et al. found a significant association between intraepithelial TILs and survival in ovarian cancer patients. 19 More specifically, cytotoxic CD81 T lymphocytes have been significantly correlated with survival in ovarian cancer in many independent studies. 8, 10, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [42] [43] [44] [45] In fact the balance between cytotoxic and suppressive T cells present in ovarian cancer may be more informative with some showing an improved overall survival with an increased intra-tumoral CD8/Tregs 8 or CD8 1 CD4/Tregs ratio. 46 However, currently available data are contradictory with some studies even showing a favorable effect of Treg infiltration on survival. 32, 33 Nevertheless, the prevailing view is that the presence of Tregs in the ovarian tumor microenvironment restrains the ability of the immune system to destroy cancer cells. 17 The presence of other immune cells has been evaluated in ovarian tumors with contradictory results. A CD191 B cell infiltrate was associated with a poorer survival in a study of 49 omental specimens from high grade ovarian cancer 47 and in a study of 59 patients with metastatic ovarian cancer. 48 In other reports, CD201 B cells were associated with improved survival in a group of 199 ovarian cancer patients, 32 and another study demonstrated their co-localization with CD8 1 TILs and a better survival rate in patients demonstrating both CD201 and CD81 TILs as compared to those showing CD8 1 TILs infiltration alone. 28 Putative Immune Modulatory Effects of Carboplatin and Paclitaxel (Fig. 2) Conventional cytotoxics may harness the anti-tumor immune microenvironment in a number of ways including the induction of cellular rearrangements that make the tumor cell more visible to host immune surveillance, or by inducing immunogenic cell death (ICD) through tumor cell surface induction of calreticulin (Fig. 1) . 49 Chemotherapy-induced cell lysis releases tumor associated antigens which are subsequently processed by dendritic (DCs) and other antigen-presenting cells (APCs). This process augmented by ICD signals emitted by dying tumor cells has been shown to prime cytotoxic T cells and promote the trafficking of interferon gamma-activated CD81 cells into tumor tissue. 50 However, ICD has mainly been attributed to anthracyclines, cyclophosphamide or oxaliplatin. With regards to cytotoxics commonly used as neoadjuvant treatment for ovarian cancer there is increasing data to support that both carboplatin and paclitaxel may subvert tumorinduced immunosuppressive mechanisms and exert stimulatory effects on immune effectors (Fig. 2) . In mouse models, paclitaxel increased MHC class I expression and upregulated antigen-processing machinery thus promoting DC antigen-presenting capacity to T-cells. 51, 52 Paclitaxel has been shown to induce the activation of dendritic cells (DCs), natural killer (NK) and tumor-specific cytotoxic T cells via the secretion of IL-12 and TNF-a and inducible nitric oxide synthase (iNOS) by macrophages. 53 Taxanes have also been shown to deplete FOXP31 regulatory cells and myeloid derived suppressor cells while polarizing macrophages to an M1 phenotype. [54] [55] [56] Platinum increased intra-tumor CD41
and CD81 T cell trafficking in esophageal cancer patient samples 57 and both cisplatin and paclitaxel upregulated mannose-6-phosphatase receptors on tumor cells and increased their permeability to granzyme or perforins secreted by activated cytotoxic T cells. 58 Carboplatin and paclitaxel have been reported to synergistically augment tumor-specific CD81 cytotoxic responses in both mouse models and patients. 59 In vitro, the combination of carboplatin and paclitaxel promoted dendritic cell activation and tumor phagocytosis as well as T-cell priming. Circulating levels of T and NK cell subsets have been monitored in ovarian cancer patients treated with carboplatin and paclitaxel and revealed that prior to treatment patients were immunocompromised as evidenced by increased Tregs and decreased cytotoxic, helper T cells and NK cells. A single cycle of treatment reversed this immunosuppression, peaking 2 weeks after treatment prompting the authors to suggests 2 weeks following chemotherapy as the optimal time to introduce an immune checkpoint inhibitor. 60 In contrast, others have suggested that the best window to achieve synergy between cytotoxics and immune therapies is 1-2 days after chemotherapy 61 While most of these experiments were conducted in vitro, they have generated a recent interest in evaluating the impact of chemotherapy on the tumor microenvironment in paired tumor samples from patients before and after neoadjuvant chemotherapy (NACT) ( Table 1) .
Effect of Neoadjuvant Chemotherapy (NACT) on TILs: Lessons from Breast Cancer Studies
Given the genomic homology between triple-negative breast cancer and the most common epithelial ovarian tumor, high grade serous ovarian cancer, some insight into the impact of NACT on the immune landscape may be gained from studies conducted in breast cancer.
Dieci et al. showed, in 278 patients with triple-negative breast cancers, that the density of TILs after NACT increased in 85% of the cases compared to pre-NACT levels and that the presence of TILs in residual disease was associated with improved prognosis. 62 67 showed that NACT results in decreased FOXP31
infiltrates. Taken together these data support the hypothesis that chemotherapy can modify the distribution of lymphocyte subpopulations. The prevailing view is that recruitment of activated CD81 cytotoxic (granzyme B and TIA1 positive cells) T cells post-NACT is associated with a better outcome 65, 67, 68 and that an immunologic profile combining low/ absence of immunosuppressive FOXP3 cells and high number of activated CD8 1 T cells in residual breast tumors post-NACT is associated with improved survival 67, 68 highlighting the importance of the balance between cytotoxic and suppressive T cells. It is, however, conceivable that NACT may have more pronounced immune modulatory effects in breast cancer where both the type of chemotherapy (anthracyclines and/or cyclophosphamide) and the overall lower disease burden may result in a more favorable immune response.
Immune Modulatory Effects of Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer
Given that an increasing number of patients with advanced epithelial ovarian cancer are treated with NACT, studies have evaluated the change in immune parameters with neoadjuvant chemotherapy through a qualitative and quantitative analysis of TIL subpopulations (Table 1 ). In a recent study involving 150 patients including 83 paired patients (pre-and post-NACT), we demonstrated a significant increase in the level of stromal TILs following NACT (p 5 0.0005) and in multivariate analysis, high stromal TILs post-NACT remained prognostic for progression free-survival. 69 Importantly when considering individual patients, the immune modulatory effects of NACT were variable and likely reflect the heterogeneity of EOC. While over half of EOCs showed a recruitment of stromal TILs and/or intraepithelial TILs, a quarter showed a decrease in TILs suggesting that NACT may have either stimulatory or suppressive effects on the tumor microenvironment. Similarly, NACT had an important impact on PDL1 expression with the proportion of PDL11 tumors increasing significantly from 30% to 53% post-NACT (p 5 0.03). A significant increase in TILs with neoadjuvant chemotherapy has been described in other studies.
In a study analyzing intraepithelial TILs in 30 patients with advanced EOC, pre-and post-NACT, Polcher et al. showed a significant increase in CD41 (2.5-fold), CD81 (2.5-fold) and Granzyme B1 (2.5-fold) cells after NACT while FOXP31 cell numbers were unchanged. Their results argue for a differential effect of NACT on recruitment or expansion of activated T cells vs. Tregs. 45 Similarly, in a cohort of 26 paired patients (pre-and post-NACT), Lo et al. demonstrated a significant increase in CD31 (p 5 0.013), CD81 (p 5 0.006), CD201 (p 5 0.006) and PD11 (p 5 0.012) intraepithelial TILs as well as a trend toward increased density of CD4 1 T cells following NACT while intraepithelial FOXP31 and IDO-11 cells exhibited no significant change after NACT. Our study described three response patterns to NACT where tumors with initially high immune markers showed even higher expression after NACT; tumors with initial low/intermediate TILs underwent similar increases, achieving patterns indistinguishable from the first group; and finally tumors with no TILs generally remained negative. 45, 70 These observations highlight the variable effect of NACT on the tumor microenvironment.
However, the described significant increase in TILs with neoadjuvant chemotherapy is not unanimous. From a study done on 54 patients with HGSC, Bohm et al. analyzed 25 paired patients for T cell density variation with chemotherapy and were unable to show a significant difference in CD8, CD4, CD3 or CD451 TILs density pre-and post NACT but described significantly fewer FOXP3 1 TILs (p 5 0.02) in the group with good therapeutic response after NACT and an increase in the expression of co-regulatory molecules such as PD1, CTLA4 and PDL1 (p 5 0.03). They also demonstrated an increase in T cell activation with enhanced IFN production by CD41 T cells and increase antitumor Th1 gene signatures, especially among patients with a good response to NACT. 71 These studies highlight the wide spectrum of NACT effects on tumor immune contexture and suggest that the immune profile of the post-treatment (not diagnostic) tumor should be considered when selecting patients for immune therapies.
Prognostic Impact of TILs After NACT
Interestingly, none of the studies evaluating immune subpopulations after NACT found that CD41, CD81 or CD31 TIL levels were prognostic. 12, 45, 70, 71 Even the ratio of CD81/ CD41 TILs showed contradictory results, it was predictive of improved survival in Polcher's study 45 but not contributory in Bohm's study. 71 The discordant prognostic significance of the CD81 immune infiltrate was highlighted by Wouters et al. 12 Our study compared TILs infiltration in advanced stage HGSC patients treated primarily with either surgery (134 patients) or neoadjuvant chemotherapy (121 patients). They found that CD8 1 TILs were only prognostic for patients treated with primary surgery resulting in complete cytoreduction, while CD27 1 CD81 TILs (CD27 being a key marker for less differentiated yet tumor-reactive CD81 TIL subset) were associated with an improved prognosis even in patients with incomplete cytoreduction. Neither CD81 nor CD271 cell infiltration post NACT was prognostic in patients treated with neoadjuvant chemotherapy 12 The lack of prognostic benefit associated with increased CD81/CD41/CD31 TILs in patients after NACT may be explained by the concomitant upregulation in co-inhibitory molecules. [69] [70] [71] We have previously shown that two-thirds of patients with PDL1-negative TILs at diagnosis demonstrate PDL1-positive immune cells after NACT and that patients with high sTILs post-chemotherapy were significantly more likely to be PD-L1-positive, suggesting activation of this immunosuppressive mechanism as a regulatory response to immune stimulation during chemotherapy. 69 PD1 is a molecule expressed on T-cells blocking their entry into the cell cycle and the production of cytokines 72 while its ligand, PDL1 causes apoptosis of T-cell upon up regulation 73 and helps the tumor evade immune destruction. 74 Hence, the potential beneficial effects of chemotherapy in stimulating Tcell recruitment might be offset by simultaneous increases in immune suppressive signaling via PD1, CTLA4 or other coregulatory molecules. 71 While FoxP31 infiltration offers little prognostic information at diagnosis, its change with NACT appears to be more informative. Patients showing a decrease in FoxP31 T lymphocytes post-NACT have an improved prognosis. 45, 71 Polcher et al. also demonstrated a significant increase in Granzyme B1 T-cells after NACT which was associated with an improvement in PFS. Granzyme B is a granule-associated protein crucial for cytolytic function that is constitutively expressed by NK cells and by activated CD81 CTLs. 75 In accordance, they highlighted that an increase in Granzyme B1/FoxP3 ratio was positively associated with PFS. 45 Changes in levels of other immune cells, such as NK cells, neutrophils, B cells or macrophages with NACT, have been less well characterized. Although one study found no difference in CD791 B cells, CD1381 plasma cells or CD681 macrophages after NACT and no association with prognosis. 70 Part of the difficulty in deciphering the prognostic impact of immune subpopulations in ovarian cancer samples taken after chemotherapy stems from the fact that data generated to date are based on a collection of often small and heterogeneous retrospective studies using different neoadjuvant chemotherapy regimens, antibodies, markers and cut-offs. These factors may have contributed to the observed differences between the studies. In addition, there is currently no standardized approach to evaluate TILs in EOC, the difference between intraepithelial/stromal/intratumoral/peritumoral TILs is poorly defined. In contrast, in breast cancer, a recommended method of evaluation has been published by the international TILs Working Group where both stromal TILs and intraepithelial TILs have been well defined and assessed as independent parameters. 76 Other aspects contributing to variable results also include pre-analytical factors or patient and tumor-related factors sample fixation protocols, time interval between last chemotherapy cycle and sample procurement, disease stage and histology. Finally, a more comprehensive evaluation of immune parameters in anatomically distinct areas from both primary ovarian tumors and multiple synchronous peritoneal metastases would be crucial to elucidate how intratumor heterogeneity may contribute to the differences in immune profiles observed before and after chemotherapy.
Despite some variability among studies, likely attributable to pre-analytical variables, differences in antibodies used, as well as inter-patient and intra-tumoral heterogeneity, the overall message from available studies in ovarian (and breast) cancers support that the balance of effector to suppressor immune cells in residual tumors post-NACT is most relevant to prognosis. For example, the combination of high levels of activated cytotoxic TILs, which recognize and kill tumor cells, and low or undetectable FOXP31 TILs, which have a critical role in suppressing anti-tumor immunity, is most often associated with improved survival. Future studies will need to be compare the prognostic value of immune parameters at diagnosis and after NACT to determine which contribute most to clinical outcome.
Therapeutic Implications
Incorporating information regarding the local immunological reaction to NACT may lead to a more effective and personalized immune strategy in ovarian cancer. Treatment of EOC remains a significant challenge with an unmet need for new strategies to reduce the high rates of relapse and mortality among patients with advanced disease. Trials of immunotherapy in EOC have been conducted in unselected, heavily pretreated patients with potential immune exhaustion and resulted in only modest response rates 77 A more appropriate strategy may be immunotherapy as maintenance after primary treatment in selected patients, in an effort to harness the host immune system and target the minimal residual disease that drives relapse.
The post-neoadjuvant setting provides the ideal window to introduce an immunotherapy:
i. the choice of treatment can be adapted to the "real-time" picture of the tumor immune microenvironment by analyzing the tumor at interval debulking, and ii. the immune therapy is introduced into the treatment sequence when it has the highest chance for efficacy, e.g. after complete debulking has reduced tumor burden to microscopic disease.
Importantly, an increasing number of immune therapies are in development targeting various co-regulatory (IDO, TIM3, LAG3, CCR2, CSF1R, GITR, OX40, ICOS) molecules on T-cells and macrophages. Future trials should evaluate individualized immune strategies, where maintenance treatment is selected on the basis of the tumor immune profile post-NACT (Fig. 3) . Patients with a lymphocyte-rich, PD-L1-positive tumor microenvironment post-NACT could be offered PD-1/PD-L1 blockade as maintenance. For select patients with a lymphocyte-rich, PD-L1-negative tumor microenvironment post-NACT, the immune strategy could be adapted to the expression of other co-inhibitory (TIM3, LAG3, IDO) or co-stimulatory molecules (OX40, GITR). In the case of high FoxP3 T regulatory cells, the balance could be shifted back in favor of cytotoxic T cells via Treg targeting with antibodies against CCR4, while in the case of high levels of "pro-tumor" M2-polarized macrophages, immune strategies targeting macrophages could be proposed. Finally those with lymphocyte-poor, PD-L1-positive tumors post-treatment could be treated with PD-1/PD-L1 blockade in combination with an adjunctive treatment (therapeutic vaccine or anti-CTLA4) to reinforce endogenous TILs trafficking and activity to maximize potency and benefit.
Performing biomarker analyses on ovarian cancer samples obtained at interval debulking after chemotherapy presents practical challenges. Epithelial ovarian cancer is typically chemo-sensitive and most of the tumor may be sterilized by treatment. However, contrary to breast cancer, actual complete pathological responses are exceedingly rare (<5%), so there is almost always residual viable tumor tissue. An increasing number of studies have confirmed that the procurement of research quality paired sequential samples from patients treated with neoadjuvant chemotherapy was feasible. 71, [78] [79] [80] This requires close collaboration between researchers and both surgeons and pathologists to optimize the selection, processing and fixation of informative tumor samples.
An evaluation of the impact of NACT on immune-related gene profiles may offer a more functional read-out of the immune contexture of residual tumors and could be investigated in future trials of neoadjuvant chemotherapy alone or in combination with novel targeted and immune therapies. Finally neoadjuvant strategies may require further optimization to enhance synergy between immune and cytotoxic therapies, it will be critical to determine the optimal timing and sequence of these agents. In addition, neither carboplatin nor paclitaxel induce immunogenic cell death (ICD), whether the immune modulatory benefits of a neoadjuvant approach could be enhanced by including classical ICD-inducers such as doxorubicin or cyclophosphamide could provide a promising approach.
Conclusion
It has been quite clearly established that TIL accumulation in ovarian tumors is an important prognostic factor for survival. However, a small number of studies have now shown that neoadjuvant chemotherapy can disrupt the tumor immune microenvironment by increasing cytotoxic (CD81) T cells, decreasing Tregs and altering the expression of immune coinhibitory molecules such as PDL1 or CTLA4. We recommend further studies on bigger cohorts to decipher the immune changes occurring at the tumor bed after NACT. In the future one could envision a truly individualized approach taking into account the tumor immune reaction to NACT, whereby after initial treatment patients with EOC are stratified to maintenance according to both the type of immune subpopulations and the expression of co-regulatory molecules identified in the tumor after chemotherapy at interval debulking.
Personalized medicine with an incorporation of the appropriate maintenance immunotherapy on the basis of the tumor immune profile after neoadjuvant chemotherapy may prove to be a promising approach to eradicate minimal residual disease and improve the outcome for patients with advanced ovarian cancer.
